Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker VRCA
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | Noah L. Rosenberg CMO | VRCA Verrica Pharmaceuticals Inc. | Buy | 2,030 | $4.92 | $9,988 Buy | Form 4 ↗ |
| Aug 18, 2026 | John J. Kirby Interim CFO | VRCA Verrica Pharmaceuticals Inc. | Buy | 5,000 | $4.93 | $24.6K Buy | Form 4 ↗ |
| Aug 17, 2026 | David Zawitz Chief Operating Officer | VRCA Verrica Pharmaceuticals Inc. | Buy | 6,000 | $4.98 | $29.9K Buy | Form 4 ↗ |
| Aug 17, 2026 | Jayson Rieger CEO and President, Director | VRCA Verrica Pharmaceuticals Inc. | Buy | 5,000 | $4.91 | $24.6K Buy | Form 4 ↗ |
| Aug 17, 2026 | Noah L. Rosenberg CMO | VRCA Verrica Pharmaceuticals Inc. | Buy | 4,200 | $4.91 | $20.6K Buy | Form 4 ↗ |
| Aug 14, 2026 | Jayson Rieger CEO and President, Director | VRCA Verrica Pharmaceuticals Inc. | Buy | 20,000 | $5.06 | $101.2K Buy | Form 4 ↗ |
| Nov 25, 2025 | David Zawitz Chief Operating Officer | VRCA Verrica Pharmaceuticals Inc. | Buy | 10,000 | $4.24 | $42.4K Buy | Form 4 ↗ |
| Nov 25, 2025 | Jayson Rieger CEO and President, Director | VRCA Verrica Pharmaceuticals Inc. | Buy | 94,311 | $4.24 | $399.9K Buy | Form 4 ↗ |
| Nov 25, 2025 | Noah L. Rosenberg CMO | VRCA Verrica Pharmaceuticals Inc. | Buy | 2,357 | $4.24 | $9,994 Buy | Form 4 ↗ |
| Nov 25, 2025 | John J. Kirby Interim CFO | VRCA Verrica Pharmaceuticals Inc. | Buy | 3,536 | $4.24 | $15.0K Buy | Form 4 ↗ |
| Nov 25, 2025 | Paul B. Manning Director, 10% owner | VRCA Verrica Pharmaceuticals Inc. | Buy | 2.75M | $4.24 | $11.7M Buy | Form 4 ↗ |
| Nov 25, 2025 | Paul B. Manning Director, 10% owner | VRCA Verrica Pharmaceuticals Inc. | Buy | 1.38M | $4.24 | $5.8M Buy | Form 4 ↗ |
| Mar 17, 2025 | Christopher G. Hayes CHIEF LEGAL OFFICER | VRCA Verrica Pharmaceuticals Inc. | Sale | 4,315 | $0.65 | $2,805 Sale | Form 4 ↗ |
| Nov 22, 2024 | Jayson Rieger CEO and President, Director | VRCA Verrica Pharmaceuticals Inc. | Buy | 280,898 | — | — Buy | Form 4 ↗ |
| Nov 22, 2024 | John A. Stalfort III Director | VRCA Verrica Pharmaceuticals Inc. | Buy | 1.12M | — | — Buy | Form 4 ↗ |
| Nov 22, 2024 | Paul B. Manning Director, 10% owner | VRCA Verrica Pharmaceuticals Inc. | Buy | 4.49M | — | — Buy | Form 4 ↗ |
| Nov 22, 2024 | Paul B. Manning Director, 10% owner | VRCA Verrica Pharmaceuticals Inc. | Buy | 18.43M | — | — Buy | Form 4 ↗ |
17 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:58 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances